CD274 and neoplasm: Furthermore, MiBaMc shows potent tumor inhibition ability in two tumor-bearing mouse models (immunogenic triple-negative breast cancer and colorectal cancer) when combined with clinically approved anti-PDL1 blocking antibody (aPDL1).